Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter?

Blood

Volumn 98, Issue 10, 2001, Pages 2900-2908

  Körbling, Martin ^a   Anderlini, Paolo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESSORY CELL; ACUTE LEUKEMIA; ALLOGRAFT; ALLOTRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; FETUS LIVER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL; SURVIVAL; UMBILICAL CORD BLOOD;

EID: 0035892108     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.2900     Document Type: Article

References (77)

1. Thomas ED, Storb R. Technique for human marrow grafting. Blood. 1970;36:507-515.
2. Thomas DB. The infusion of human fetal liver cells. Stem Cells. 1993;11(suppl 1):66-71.
3. Körbling M, Burke P, Braine H, Elfenbein G, Santos G, Kaizer H. Successful engraftment of blood-derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol. 1981;9:684-690.
4. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174-1178.
5. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995;86:2842-2848.
6. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion. 1999;39:39-47.
7. DiPersio J, Khoury H, Haug J, et al. Innovations in allogeneic stem-cell transplantation. Semin Hematol. 2000;37(suppl 2):33-41.
8. Lebsack ME, McKenna HJ, Hoek JA, et al. Safety of FLT-3 ligand in healthy volunteers [abstract]. Blood. 1997;90(suppl 1):170.
9. dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Transfusion. 1997;37:406-410.
10. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematological cancers. N Engl J Med. 2001;344:175-181.
11. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996;88:2775-2779.
12. Lebsack ME, McKenna HJ, Hoek J, Feng A, Maraskovsky E, Hayes FA. FLT3 ligand (Mobist) administered in combination with GM-CSF or G-CSF to healthy volunteers [abstract]. J Clin Oncol. 1998;17:78.
13. Couban S, Messner HA, Andreou P, et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients. Biol Blood Marrow Transplant. 2000;6:422-427.
14. Körbling M, Giralt S, Khouri I, et al. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apheresis. 2001;16:82-87.
15. Chiu C-P, Dragowska W, Kim NW, et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 1996;14:239-248.
16. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MAS. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000;60:610-617.
17. Lansdorp PM. Stem cell biology for the transfusionist. Vox Sang. 1998;74(suppl 2):91-94.
18. Verfaillie CM, Almeida-Porada G, Wissink S, Zanjani ED. Kinetics of engraftment of CD34(-) and CD34(+) cells from mobilized blood differs from that of CD34(-) and CD34(+) cells from bone marrow. Exp Hematol. 2000;28:1071-1079.
19. Giralt S, Korbling M. Unpublished data. 2001.
20. Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, McCullough J. Treatment of normal donors with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36:601-610.
21. Anderlini P, Donato M, Chan KW, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999;39:555-560.
22. Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45-49.
23. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor [letter]. Lancet. 1999;353:555.
24. Parkkali T, Volin L, Sirén MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant. 1996;17:433-434.
25. Spitzer T, McAfee S, Poliquin C, Colby C. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor in an allogeneic blood stem cell donor [letter]. Bone Marrow Transplant. 1998;21:966-967.
26. Adkins DR. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor [letter]. J Clin Oncol. 1998;16:812.
27. Vij R, Adkins DR, Brown RA, Khoury H, DiPersio JF, Goodnough T. Unstable angina in a peripheral blood stem and progenitor cell donor given granulocyte-colony-stimulating factor [letter]. Transfusion. 1999;39:542-543.
28. Anderlini P, Körbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903-908.
29. Anderlinl P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27:689-692.
30. Bortin MM, Buckner CD. Major complications of marrow harvesting for transplantation. Exp Hematol. 1983;11:916-921.
31. Stroncek DF, Holland PV, Bartch G, et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993;81:1940-1946.
32. Hasenclever D, Sextro M. Safety of alloPBSCT donors: biometrical considerations on monitoring long term risks [abstract]. Bone Marrow Transplant. 1996;17(suppl 2):S28.
33. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25:85-89.
34. Hassan HT, Stockschlader M, Schleimer B, Kruger W, Zander AR. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transplant immunol. 1996;4:319-323.
35. Anderlini P, Körbling M, Chan K-W, Champlin R, Strom S. Long-term follow-up and safety of normal peripheral blood progenitor cell (PBPC) donors treated with filgrastim: the MD Anderson Cancer Center experience. Proceedings of the 43rd ASH Annual Meeting, Orlando, 2001. In press.
36. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood. 1987;70:227-232.
37. Gluckman E, Socié G, Guivarch C, Rabannes F, Meresse V, Henry-Amar. The long-time forgotten HLA identical bone marrow donor: result of a survey on 818 patients [abstract]. Blood. 1996;88:612.
38. Vigorito AC, Azevedo WM, Marques JFC, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22:1145-1151.
39. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstimprimed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537-546.
40. Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94:455-464.
41. Heldal D, Tjonnfjord G, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 2000;25:1129-1136.
42. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355:1231-1237.
43. Schmitz N, Beksac M, Hasenclever D, et al. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilized peripheral blood progenitor cells with bone marrow transplantation in 350 patients (pts) with leukemia [abstract]. Blood. 2000;96:481.
44. Simpson DR, Couban S, Bredeson C, et al. A Canadian randomized study comparing peripheral blood (PB) and bone marrow (BM) in patients undergoing matched sibling transplants for myeloid malignancies [abstract]. Blood. 2000;96:481.
45. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95:3702-3709.
46. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838-1845.
47. Cutler C, Girl S, Jeyapalan S, Paniagua D, Viswanathan A, Antin J. Incidence of acute and chronic GVHD after allogeneic peripheral blood stem cell and marrow transplantation: a metaanalysis [abstract]. Blood. 2000;96:205.
48. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading, and treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 1989;4:247-254.
49. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
50. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The risk of residual molecular and cytogenetic disease in patients with Philadelphia chromosome-positive first chronic phase myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with marrow. Blood. 1999;94:3884-389.
51. Shenoy S, Mohanakumar T, Todd G, et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23:335-346.
52. + cell transplants. Exp Hematol. 2000;28:119-127.
53. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.
54. Rachamim N, Gan J, Segall H, et al. Tolerance induction by "megadose" hematopoietic transplants. Transplantation. 1998;65:1386-1393.
55. Claesson MH, Miller RG. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones, I: CTL clones express strong anti-self suppressive activity. J Exp Med. 1984;160:1702-1716.
56. + CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity. 2000;13:507-515.
57. Reisner Y et al. Unpublished data. 2001.
58. Janssen WE, Perkins J, Hiemenz JW, et al. Granulocyte recovery is not different following auto-transplant with G-CSF primed bone marrow or G-CSF primed blood "stem cells" [abstract]. Blood. 1994;84:95.
59. Isola L, Scigliano E, Fruchtman S. Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation. Biol Blood Marrow Transplant. 2000;6:428-433.
60. Serody JS, Sparks SD, Lin Y, et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant. 2000;6:434-440.
61. Pan LY, Delmonte J Jr, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429.
62. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T-helper 2-inducing dendritic cells. Blood. 2000;95:2484-2490.
63. Pan L, Delmonte J Jr, Jalonen CK, Ferrara LM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1998;86:4422-4429.
64. Liu Y-J, Blom B. Introduction: TH2-inducing DC2 for immunotherapy. Blood. 2000;95:2482-2483.
65. Reddy V. Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper 2 polarization prior to host alloantigen presentation [letter]. Blood. 2000;96:2635.
66. Pan L, Teshima T, Hill GR, et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 1999;93:4071-4078.
67. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cells are diminished in granulocyte-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood. 1997;90:3098-3105.
68. Rondelli D, Raspodiri D, Anasetti C, et al. Alloantigen capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant. 1998;22:631-637.
69. Verma UN, Yankelevich B, Hodgson J, Mazumder A. Effect of the in vivo priming regimen for peripheral blood stem cells (PBSC) mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in a murine model. Bone Marrow Transplant. 1997;19:265-273.
70. Kitabayashi A, Hirokawa M, Hatano Y, et al. Granulocyte colony-stimulating factor down-regulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-α production. Blood. 1995;86:2220-2227.
71. Volpi I, Perruccio K, Tosti A, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 2001;95:2514-2521.
72. Romani L. The T cell response against fungal infections. Curr Opin Immunol. 1997;9:484-490.
73. Vij R, Brown RA, Adkins D, et al. Mobilization of normal donors with G-CSF + GM-CSF is associated with improved yield of hematopoetic progenitors and increased numbers of activated dendritic cells [abstract]. Blood. 1998;90(suppl 1):682.
74. Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol. 2000;165:566-572.
75. Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J. Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol. 1995;89:465-472.
76. Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood. 1997;89:1629-1634.
77. Ageitos AG, Varney ML, Bierman PJ, Vose JM, Warkentin PI, Talmadge JE. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Bone Marrow Transplant. 1999;23:63-69.